Clinical Trials Browser

Phase 1/2 × Recruiting × Osteosarcoma × Clear all

Osteosarcoma

NCT06625190 2026-03-11

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Chordoma, Myoepithelioma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Nerve Sheath Neoplasms, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT06541262 2026-03-02

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Phase 1/2 Recruiting

104 enrolled

CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT04851119 2026-02-24

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 1/2 Recruiting

147 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Phase 1/2 Recruiting

63 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

NCT04901702 2026-02-09

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Phase 1/2 Recruiting

90 enrolled

CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT05642455 2026-02-09

SPEARHEAD-3 Pediatric Study

Phase 1/2 Recruiting

20 enrolled

CNSSarcoma

Neuroblastoma, Osteosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT07357519 2026-02-09

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Phase 1/2 Recruiting

55 enrolled

Sarcoma

Osteosarcoma

NCT06239272 2026-01-26

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

139 enrolled

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT07066982 2025-07-15

BAH2573-103

Phase 1/2 Recruiting

60 enrolled

LymphoidSarcoma

Lymphoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Kaposi, Osteosarcoma, Sarcoma, Synovial

NCT05588648 2025-04-10

Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Phase 1/2 Recruiting

48 enrolled

Sarcoma

Osteosarcoma

NCT06778603 2025-01-16

ROLN-B7-H3

Phase 1/2 Recruiting

32 enrolled

Sarcoma

Margins of Excision, Osteosarcoma

Clinical Trials

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

SPEARHEAD-3 Pediatric Study

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

BAH2573-103

Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

ROLN-B7-H3